GlassScriptPhysician profile
Marcy Gabay
NPI 1760791578
$1,647.76
in general payments reported to CMS, 2019-2025
19 companies · $841 in 2025
The $841 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $110 · 2023: $238 · 2024: $459 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $395.05 | 2024-2025 | |
| Janssen Biotech, INC. | $319.27 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.22 | 2023-2025 | Xifaxan, Relistor |
| Ardelyx, INC. | $142.36 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $116.05 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Intercept Pharmaceuticals, INC. | $80.91 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $71.90 | 2023-2024 | Dificid |
| Cumberland Pharmaceuticals, INC. | $54.02 | 2023 | Kristalose |
| Celltrion USA INC. | $45.12 | 2025 | Vegzelma |
| Vivus LLC | $35.13 | 2024-2025 | Pancreaze |
| Genzyme Corporation | $30.42 | 2025 | |
| Aimmune Therapeutics, INC. | $30.17 | 2024 | |
| Alnylam Pharmaceuticals INC. | $29.38 | 2022 | |
| Lilly USA, LLC | $27.81 | 2023 | |
| Phathom Pharmaceuticals, INC. | $24.08 | 2024 | Voquezna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $17.46 | 2025 | |
| Celgene Corporation | $17.33 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $16.00 | 2024 | Resmetirom |
| Nestle Healthcare Nutrition INC. | $14.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy Gabay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.